Investors sentiment increased to 1.8 in 2019 Q2. Its up 0.80, from 1 in 2019Q1. It increased, as 3 investors sold Agile Therapeutics, Inc. shares while 2 reduced holdings. 3 funds opened positions while 6 raised stakes. 17.90 million shares or 6.19% more from 16.86 million shares in 2019Q1 were reported.
Vanguard Grp has invested 0% in Agile Therapeutics, Inc. (NASDAQ:AGRX). 100,000 are owned by Highland Cap Mngmt Limited Partnership. Bank & Trust Of Ny Mellon holds 0% or 30,829 shares in its portfolio. Tower Rech Cap (Trc) reported 1,903 shares stake. 227,937 were reported by Royal Retail Bank Of Canada. Jpmorgan Chase Company accumulated 76,538 shares. Blackrock holds 0% or 169,226 shares in its portfolio. Needham Invest Mngmt Limited Liability Com has 95,000 shares for 0.05% of their portfolio. Moreover, Fosun Ltd has 0.04% invested in Agile Therapeutics, Inc. (NASDAQ:AGRX). 450,180 are held by Acadian Asset Mgmt Limited Liability. Perceptive Advsr Lc holds 0.24% of its portfolio in Agile Therapeutics, Inc. (NASDAQ:AGRX) for 8.43M shares. 281,210 are held by Geode Cap Management Limited Liability Corp. Northern Corporation holds 40,923 shares. Investor Ab holds 0.27% in Agile Therapeutics, Inc. (NASDAQ:AGRX) or 3.51M shares. The Illinois-based Group One Trading Ltd Partnership has invested 0% in Agile Therapeutics, Inc. (NASDAQ:AGRX).
The stock of Agile Therapeutics, Inc. (NASDAQ:AGRX) is a huge mover today! The stock decreased 1.94% or $0.04 during the last trading session, reaching $2.02. About 1.58 million shares traded. Agile Therapeutics, Inc. (NASDAQ:AGRX) has risen 314.29% since December 4, 2018 and is uptrending. It has outperformed by 314.29% the S&P500.
The move comes after 6 months negative chart setup for the $119.79 million company. It was reported on Dec, 4 by Barchart.com. We have $1.84 PT which if reached, will make NASDAQ:AGRX worth $10.78M less.
Analysts await Agile Therapeutics, Inc. (NASDAQ:AGRX) to report earnings on March, 10. They expect $-0.08 EPS, up 27.27 % or $0.03 from last year’s $-0.11 per share. After $-0.08 actual EPS reported by Agile Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 0.00 % EPS growth.
Agile Therapeutics, Inc. (NASDAQ:AGRX) Ratings Coverage
Among 3 analysts covering Agile Therapeutics (NASDAQ:AGRX), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Agile Therapeutics has $4 highest and $2 lowest target. $3’s average target is 48.51% above currents $2.02 stock price. Agile Therapeutics had 9 analyst reports since June 7, 2019 according to SRatingsIntel. The rating was maintained by Maxim Group on Friday, October 11 with “Buy”. Oppenheimer maintained the shares of AGRX in report on Tuesday, October 29 with “Buy” rating. Maxim Group maintained the shares of AGRX in report on Thursday, October 31 with “Buy” rating. The firm has “Buy” rating given on Tuesday, October 29 by RBC Capital Markets.
More notable recent Agile Therapeutics, Inc. (NASDAQ:AGRX) news were published by: Nasdaq.com which released: “BUZZ-U.S. STOCKS ON THE MOVE-J.C. Penney, JD.com, Occidental, RH, Applied Materials – Nasdaq” on November 15, 2019, also Benzinga.com with their article: “Stocks That Hit 52-Week Highs On Wednesday – Benzinga” published on November 06, 2019, Seekingalpha.com published: “ChemoCentryx leads healthcare gainers; Akers Biosciences among losers – Seeking Alpha” on November 26, 2019. More interesting news about Agile Therapeutics, Inc. (NASDAQ:AGRX) were released by: Nasdaq.com and their article: “Agile Therapeutics (AGRX) Upgraded to Buy: Here’s What You Should Know – Nasdaq” published on October 25, 2019 as well as Seekingalpha.com‘s news article titled: “VKTX, JKS among premarket gainer – Seeking Alpha” with publication date: November 19, 2019.
Agile Therapeutics, Inc., a forward-thinking women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. The company has market cap of $119.79 million. The Company’s lead product candidate is Twirla, also known as AG200-15, a once-weekly contraceptive patch, which completed Phase III clinical trials. It currently has negative earnings. The firm is also developing a pipeline of other new transdermal contraceptive products, including AG200-ER, a regimen that allows a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide shorter lighter periods; and AG890, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.